Science Corp. Announces European Commercial Launch of PRIMA, the Only Treatment to Restore Functional Central Vision to Patients with Geographic Atrophy Caused by Age-Related Macular Degeneration

Science Corporation press release, published July 22, 2026.

• PRIMA has received a CE (Conformité Européenne) mark under the European Union Medical Device Regulation from DEKRA, authorizing its commercial availability across 30 European countries.
• PRIMA is the first BCI device to receive CE marking for form vision restoration (reading letters, numbers, and words).
• Country-specific reimbursement applications and clinical site activations are underway across Europe. The first commercial implant of PRIMA is expected soon in Germany.
• In the United States, PRIMA has received FDA Breakthrough Device designation and Humanitarian Use Device designation.
• AMD-associated GA affects more than five million people globally, causing the progressive destruction of photoreceptors at the center of the retina and eventual blindness.
• Trial results (38 patients, 17 sites, 5 countries): mean improvement of 25.5 letters (>5 lines) on ETDRS chart; 84% reported ability to read letters, numbers, and words; 80% achieved >=0.2 logMAR improvements at 12 months (p<0.001); implant placed under the atrophic macula without decline in mean existing natural vision.
• The PRIMA BCI system is a novel subretinal photovoltaic implant paired with specialized glasses; the glasses project near-infrared light, which the implant converts into electrical stimulation signals; a zoom-in feature allows magnifying letters.
• PRIMA implant measures 2 x 2 mm. Not commercially available outside the EU/EEA.